Project Grant R01CA306020
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $703K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $472,730 project grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025, through July 31, 2030. This five-year project investigates the role of the tumor suppressor KEAP1 (Kelch-like ECH-associated protein 1) in antitumor immunity, with specific focus on understanding how loss-of-function KEAP1 mutations contribute to immune...
- Federal Project Grant Award Summary The National Cancer Institute awarded Weill Medical College of Cornell University a Project Grant totaling $716,183.00 (awarded May 13, 2026; completion date April 30, 2031) under the Cancer Treatment Research program (CFDA 93.395) to investigate and optimize chimeric antigen receptor (CAR) T-cell therapies for cancer treatment. The research focuses on identifying and targeting co-inhibitory and co-stimulatory molecules that limit CAR-T cell efficacy....
- Federal Grant Award Summary The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai a $697,131 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period May 1, 2026 through April 30, 2031. This award supports fundamental research designed to elucidate the myeloid-stromal crosstalk mechanisms that drive immune suppression and tumor progression in colorectal cancer (CRC), particularly in microsatellite-stable cases resistant to immune checkpoint...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded Columbia University's Health Sciences Division a Project Grant of $257,472 effective September 6, 2025, with completion targeted for March 6, 2029. The award funds research to dissect the impact of genomic variants on T cell anti-tumor activity, specifically investigating how single-nucleotide variants (SNVs) in T cell signaling genes can enhance cellular...
- Federal Grant Award Summary This project grant from the National Cancer Institute (NCI), awarded under the Cancer Biology Research program (CFDA 93.396), provides $1.31M in funding to Weill Medical College of Cornell University to conduct fundamental research on signal transduction mechanisms related to p70 S6 kinase 1 (S6K1) and mammalian target of rapamycin complex 1 (mTORC1) signaling in cancer cells. The award, granted July 10, 2025, with a completion date of April 30, 2030, supports a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $628,394 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 8, 2026, with a completion date of April 30, 2031. The award funds research to develop and validate a novel patient-derived organoid with tumor microenvironment (PDOT) co-culture system for intrahepatic cholangiocarcinoma (ICCA), a devastating liver cancer with limited therapeutic options. The...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $204,027 project grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025 through July 31, 2030. This award supports the development and application of advanced single-cell and spatial technologies designed to link clonal genotypes with phenotypes during cancer evolution. The project addresses a critical gap in cancer research by...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Weill Medical College of Cornell University a $694,133 project grant on May 14, 2026, under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on axonal control of tumor progression in melanoma. The research project, which extends through April 30, 2031, focuses on defining how sympathetic nervous system axons inhibit melanoma growth through interactions with immune effectors in the...
- Federal Grant Award Summary The National Cancer Institute awarded the University of California, Irvine a $648,626 Project Grant on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI). The research addresses a critical gap in understanding why PD-1 inhibitor monotherapy and dual checkpoint inhibitor combinations fail in the majority of cancer patients. The study will examine...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...